在MASH治疗中通过架跳跃发现了基于英达的新型强效FXR激活剂
相关实验视频
Updated: Jan 16, 2026

05:07
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
Published on: June 23, 2019
7.0K
Da-Yu Shi1, Xin-Wei Shi1, Hang Shi2
1State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai, 201203, China; School of Pharmacy, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai, 201203, China.
European journal of medicinal chemistry
|September 30, 2025
概括
研究人员开发了一种新型化合物E2,该化合物向法尔内索伊德X受体 (FXR),用于治疗代谢相关肝炎 (MASH). 在临床前模型中,E2表现出强烈的活性和改善肝脏健康,显示出MASH治疗的前景.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
- 药用化学 医学化学
背景情况:
- 华氏体X受体 (FXR) 是胆酸,葡萄糖和脂质代谢的关键调节者.
- FXR是代谢相关肝炎 (MASH) 的验证治疗标.
- LMB763 (Nidufexor) 是一个临床阶段的FXR激动剂,在MASH模型中已证明有效性.
研究的目的:
- 设计和合成基于 LMB763 脚手架的新型 FXR 激应剂.
- 评估用于MASH治疗的新型化合物的药理性质和体内疗效.
主要方法:
- 在化合物设计和合成中采用了跳架策略.
- 试验室测试用于确定FXR激素激素活性 (EC50) 和对相关核受体的选择性.
- 评估了肝脏微体的代谢稳定性.
- 在高脂肪饮食诱导的MASH小鼠模型中评估了体内疗效.
主要成果:
- 化合物E2成为具有强大的FXR激动因子活性的主要候选物 (EC50 = 0.097 ± 0.009 μM).
- E2表现出有利的肝脏微体代谢稳定性和对非目标核受体的良好选择性.
- 在体内研究表明,E2在MASH小鼠模型中有效地改善了肝肥胖症.
结论:
- 化合物E2是MASH的有希望的治疗候选物.
- 这项研究为MASH治疗选择性FXR激动剂的设计提供了宝贵的见解.
相关概念视频
Drug Discovery: Overview
11.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.0K
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K

